Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia.
Animals
Antibodies, Bispecific
/ administration & dosage
Cell Cycle
Cell Line, Tumor
Cell Proliferation
Cell Survival
Cytotoxicity, Immunologic
Drug Synergism
Humans
Immune Checkpoint Inhibitors
/ administration & dosage
K562 Cells
Leukemia, Myeloid, Acute
/ drug therapy
Macaca fascicularis
Mice
Treatment Outcome
fms-Like Tyrosine Kinase 3
/ antagonists & inhibitors
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
21
11
2019
revised:
05
05
2020
accepted:
05
06
2020
pubmed:
11
6
2020
medline:
29
6
2021
entrez:
11
6
2020
Statut:
ppublish
Résumé
Despite advances in the treatment of acute myeloid leukemia (AML), novel therapies are needed to induce deeper and more durable clinical response. Bispecific T-cell Engager (BiTE) molecules, which redirect patient T cells to lyse tumor cells, are a clinically validated modality for hematologic malignancies. Due to broad AML expression and limited normal tissue expression, fms-related tyrosine kinase 3 (FLT3) is proposed to be an optimal BiTE molecule target. Expression profiling of FLT3 was performed in primary AML patient samples and normal hematopoietic cells and nonhematopoietic tissues. Two novel FLT3 BiTE molecules, one with a half-life extending (HLE) Fc moiety and one without, were assessed for T-cell-dependent cellular cytotoxicity (TDCC) of FLT3-positive cell lines
Identifiants
pubmed: 32518207
pii: 1535-7163.MCT-19-1093
doi: 10.1158/1535-7163.MCT-19-1093
doi:
Substances chimiques
Antibodies, Bispecific
0
Immune Checkpoint Inhibitors
0
FLT3 protein, human
EC 2.7.10.1
fms-Like Tyrosine Kinase 3
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1875-1888Informations de copyright
©2020 American Association for Cancer Research.